A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 When Administered Intravenously as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
Latest Information Update: 11 Jul 2024
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary) ; T 3011 (Primary)
- Indications Advanced breast cancer; Colon cancer; Endometrial cancer; Gastrointestinal cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Immvira Pharma
- 04 Jun 2024 Results(As of 15 Dec 2023, n=18 pts) of T3011 monotherapy administered via IV in advanced solid tumors or IP for malignant pleural effusion/ascites, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 29 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Preliminary results from an ongoing phase 1/2a study (n=10) presented at the 59th Annual Meeting of the American Society of Clinical Oncology